IFIH1 and COVID-19: Most importantly, COVID-19 and anti-MDA5-positive dermatomyositis have notable similarities in clinical features and pathogenesis, including comparable pulmonary interstitial lesions, activation of the IFN-I signaling pathway, and response to immunosuppressive therapy (32, 33).